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17-Estradiol (E2) exerts negative feedback effects at the
hypothalamo-pituitary level on serum FSH. This study inves-
tigated the effects of repeated daily administration of intra-
nasal E2 (S21400) on the pharmacokinetics (PK) of E2 and
estrone (E1) and the pharmacodynamics (PD) of FSH and as-
sessed the PK/PD relationship between E2 and FSH using
population model-dependent analysis. Postmenopausal vol-
unteers (n  24) received according to a balanced cross-over
design, two 28-d treatments separated by a 2-month wash-out
period: 300 g E2, either alone or combined with oral dydro-
gesterone (20 mg/d) during the last 14 d of one of the treat-
ments. Absorption of E2 was rapid, with maximal plasma con-
centrations at 10–30 min, returning to postmenopausal levels
within 12 h. Over the 24-h period, FSH levels showed a U curve,
with a minimum around 8 h after E2 administration. More-
over, over the treatment period, FSH basal values decreased
by 17% between d 1 and 14 and an additional 5% between d 14
and 28. A PK/PD model described these short- and mid-term
effects, possibly reflecting separate regulation mechanisms
by E2 on FSH release and biosynthesis, respectively. The ad-
ministration of progestin had no influence on E1, E2, and FSH
model parameters. This study suggests that daily transient
tissue exposure to E2 after pulsed estrogen therapy elicits
short- and mid-term effects on the gonadotropin axis. (J Clin
Endocrinol Metab 88: 5405–5413, 2003)
FSH IS A heterodimeric hormone secreted from the pitu-itary. It is composed of an -subunit that is common to
LH, TSH, and human chorionic gonadotropin and a -
subunit that is unique. Two carbohydrate chains are linked
to both - and -subunits. Glycosylation of the subunits is
involved in the biological activity of the hormones, gener-
ating 20 circulating isoforms of FSH. Gonadotropin secretion
is under the control of GnRH and gonadal peptides such as
activins, inhibins, and gonadal steroids [progesterone and
17-estradiol (E2)] (1). FSH is considered to be one of the
main hormonal markers of menopausal status (2), as levels
of the hormone are markedly increased at menopause. One
year after menopause, FSH levels are 10- to 15-fold higher
than those during the follicular phase in women of repro-
ductive age (3–5). Estrogen replacement therapy has been
shown to produce a dose-related decrease in serum FSH
levels in postmenopausal women (6) after oral E2 adminis-
tration (7) as well as after E2 administration by nonoral
routes, such as transdermal, sublingual, and intravaginal
estrogen (8–11). Although nyctemeral variations in FSH lev-
els and during the menstrual cycle have been well charac-
terized, specific data from postmenopausal women receiving
hormone replacement therapy are limited.
Intranasal administration of an aqueous E2 solution (com-
plexed with a methylated -cyclodextrin) leads to a rapid,
but short-lasting, rise in plasma E2 levels (800–1200 pg/ml).
This rise is followed by a rapid distribution to the tissues and
a return to levels observed in postmenopausal women within
8–12 h. Therefore, it introduces the concept of pulsed estro-
gen therapy (12, 13). Besides clinical advantages associated
with the transient exposure compared with oral or transder-
mal routes (lower breast and endometrial stimulation) at
doses providing the same efficacy on climacteric symptoms
or preventing postmenopausal bone loss (14, 15), the pulsed
kinetic profile of serum E2 provided by intranasal adminis-
tration represents a unique model to study the dynamic
effects of E2 on FSH levels in postmenopausal women.
The aim of the current study was to investigate the short-
and mid-term effects of intranasal E2 on the time course of
serum FSH levels assessed over a 24-h period on d 1, 14, and
28 of a 28-d treatment in postmenopausal women and to
investigate the potential effect of progestin coadministration.
Subjects and Methods
Subjects
Twenty-four healthy, Caucasian, postmenopausal women volun-
teers, aged 57  5 yr (mean  sd), with a mean body weight of 63  7
kg and a mean body mass index of 24  2 kg/m2 were included in this
study. All subjects were nonsmokers and had been menopausal for at
least 3 yr (mean, 8.2  6.0 yr). The concomitant treatments, which were
likely to change the metabolism of E2, alter the nature or development
of mucosal secretions, or modify the hypothalamo-pituitary axis regu-
lation, were not allowed. Women who had received treatment with
estrogen and/or progestogen by the oral or systemic route during the
Abbreviations: E1, Estrone; E2, 17-estradiol; h, human; PD, phar-
macodynamics; PK, pharmacokinetics.
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30 d preceding the selection visit were excluded of the study. Post-
menopausal status was confirmed by FSH values greater than 30
mIU/ml and E2 values less than 20 pg/ml. All subjects gave their
written, informed consent and underwent a complete medical exami-
nation before inclusion. The protocol of the trial was approved by the
ethics committee of Versailles, France.
Study design
This open study was performed with 24 subjects receiving during 2
periods, 2 28-d treatments with daily administration of intranasal E2
(S21400). According to a balanced, randomized, cross-over design, a
progestin was administered daily the last 14 d of 1 of the 2 treatment
periods. The first (d 1–28) and second treatment periods (d 90–117) were
separated by a 2-month wash-out (d 29–89) designed to avoid inter-
ferences between the 2 treatment periods. S21400 was administered
intranasally in the morning as a single daily dose of 300 g (1 spray/
nostril) for 28 d. Each spray had a volume of 70 l and delivered 150 g
E2. Oral progestin (20 mg/d dydrogesterone, Solvay Pharma, Suresnes,
France) was taken within 10 min before or after the intranasal admin-
istration during the last 14 d of 1 of the 2 treatment periods.
Blood sampling
Blood was collected for FSH, E2, and estrone (E1) assays before
intranasal drug administration at inclusion; on d 1, 14, and 28 of each
treatment cycle; 15 and 30 min before E2 administration; and 10, 20, 30,
and 45 min and 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 h (immediately before the
next dosing) after administration. During the wash-out period blood
was collected for E1 and E2 assays only. All samples were obtained by
venipuncture or via a forearm catheter, then collected into glass tubes
without anticoagulant before centrifugation (3000 rpm for 10 min at
room temperature). Serum samples were then aliquoted into polypro-
pylene test tubes and stored at 20 C until analyzed.
Assays
E1 and E2 concentrations were quantified in duplicate serum samples
by a method based on a modified RIA using commercial kits (Bi-
omerieux, Craponne, France) in which a liquid/liquid extraction was
followed by a chromatographic separation of the extracted steroids. An
RIA was then performed, based on a competitive inhibition reaction
between 4-fold [3H]E1 or [3H]E2 at a fixed concentration, with the steroid
contained in standards or samples to be assayed, against anti-E1 or
anti-E2 antibodies. The accuracy and precision of this assay have been
validated to be less than 20% (12), and the limits of detection were 5 and
20 pg/ml for E2 and E1, respectively.
FSH concentrations were determined in duplicate using an immu-
noradiometric assay for follitropin in human serum (FSH IRMA kit,
Biocode Biotechnology, Sclessin, Belgium). The limit of detection of this
assay was 0.23 mIU/ml, and cross-reactivity with human chorionic
gonadotropin, human (h) LH (hLH), hTSH, and hPRL was less than
0.001%. The intra- and interassay coefficients of variation assessed in the
study using Lyphocheck Immunoassay Plus Controls (Bio-Rad Labo-
ratories, Irvin, CA) were less than 4% and 10%, respectively. Six FSH
standards were used and were calibrated against the WHO Second
International Reference Preparation IRP 78/549.
Pharmacokinetic evaluation
A population model-dependent PK analysis was performed using
NONMEM software version IV level 1.2 (University of California, San
Francisco, CA), to obtain post hoc individual parameters. E1 and E2
concentration time data were fitted separately to three compartment
models that were parameterized, without taking into account the ab-
solute bioavailability (F), in terms of apparent clearance, where CL/F
(CL, total clearance), Q2/F, and Q3/F (Q2 and Q3, intercompartmental
clearance), and of apparent volumes of distribution, with Vc/F (Vc,
central compartment volume), V2/F, and V3/F (V2 and V3, peripheral
compartment volumes). The absorption of E2 and the formation of E1
were parameterized with regard to duration as a zero order process
(TK0). Basal levels of the endogenous hormones were taken into account
in the modeling. The influence of covariates was statistically tested for
the primary pharmacokinetic parameters (clearance, volumes of distri-
bution, duration of the zero order process for absorption of E2 or for-
mation of E1, and basal levels of endogenous estrogens) using the
likelihood ratio test. The covariates tested were coadministration of
progestin, single vs. repeated administration, first E2 dose (d 1 and 90)
vs. repeated administrations (d 14, 28, 103 and 117), influence of the cycle
(first vs. second cycle), and influence of the cycle day (d 1 and d 90 vs.
d 14 and d 103 vs. d 28 and d 117).
Pharmacokinetic/pharmacodynamic evaluation
A mechanistic-based model was developed, using NONMEM soft-
ware, to link the PK of E2 to the PD effects of FSH suppression. Two
PK/PD submodels were necessary to describe the dual action of E2 on
FSH. Model 1 (used to describe the inhibition of FSH secretion by E2 that
takes place within several hours) was an indirect inhibitory sigmoid
Emax model, which related plasma concentrations of E2 to FSH serum
levels. Model 2 (used to describe the inhibition of FSH biosynthesis by
E2 which takes place within several days) was a drug exposure response
time model relating the E2 exposure to the predose values of FSH. The
indirect inhibitory sigmoid Emax model (model 1) was set up according
to the following equations:
dFSH
dt
 Kin  I(t)  Kout  FSH (1)
where Kin represents the zero order constant for production of FSH, I(t)
is the inhibitory function, and Kout defines the first order rate constant
for the loss of FSH.






where Emax represents the maximum effect attributed to the drug (E2),
Cp is the plasma concentration of E2,  is the Hill factor, and IC50
represents the E2 concentration producing 50% of the maximum inhi-
bition. Model 1 assumes that under baseline conditions with no drug
administered:
Kin  Kout  FSH0 (3)
The drug exposure response time model (model 2) was set up on the
predose values of FSH (FSH0), according to the following formula:
FSH0  FSH0 initial  (1  A  AUC exp(Keq  time)) (4)
where FSH0 is the level of FSH before each administration, FSH0 initial is
the baseline value of FSH before the first E2 administration, AUC is the
E2 exposure during a dosing interval (24 h), A is a constant that when
multiplied by AUC gives the percent maximum decrease in FSH0 from
FSH0 initial, and Keq is the rate constant of equilibration, defining the
delay in the effect of E2 on the FSH biosynthesis.
Challenging the pharmacokinetic/pharmacodynamic model
To test the ability of the model to predict data coming from new
studies, the approach suggested by Bruno et al. (16), based on quanti-
tative evaluations (building data set) of model predictions on individual
subject (validation dataset) FSH concentrations, was applied. Data were
computed by Bayesian feedback. To challenge the short- and mid-term
actions of E2 on FSH levels, two validation datasets from previously
published studies (12, 13) were used: a single dose study involving three
doses of S21400 (100, 300, and 450 g) (12) and a dose-ranging study
involving four doses of S21400 (100, 200, 300, and 400 g), given once
daily for 12 wk (13).
Statistical analysis
All statistical calculations were performed using SAS 6.12 software
(SAS Institute, Inc., Cary, NC). Inter- and intrasubject variabilities of E1,
E2, and FSH model-dependent parameters were calculated by compar-
ing individual parameter values from each period of treatment. For the
PK data, six time periods were considered, one for each day of PK
evaluation (d 1, 14, 28, 90, 103, and 117). For the PD data, two periods
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were considered, one for each cycle. Data were analyzed by variance
analysis (ANOVA), which included both a subject effect and a period
effect. The intersubject variability was based on the estimate of the
subject effect. The error term of the ANOVA on untransformed values,
which accounted for unexplained phenomena, was an estimate of the




E2. The mean concentration of endogenous serum E2 in the
postmenopausal women included in the study, measured 30
min before E2 administration, was 14  7 pg/ml, and this
concentration varied only slightly throughout the day, as
assessed during the wash-out period (range, 10.4–14.5 pg/
ml). After nasal administration of 300 g E2 as S21400, the
time course of observed serum E2 concentrations was char-
acterized by relatively high levels of E2 of short duration (Fig.
1A). On d 1, the maximum mean E2 concentration observed
was 1014  505 pg/ml (mean  sd), which was reached 10
min after administration and was followed by a rapid tissue
distribution. Two and 4 h after administration, the E2 con-
centration observed represented only 13% (i.e. 132 pg/ml)
and 6% (i.e. 61 pg/ml), respectively, of the maximum mean
observed value. E2 concentrations returned to levels similar
to those in untreated postmenopausal women by 12 h. The
E2 PK profiles observed on d 1, 14, and 28 were superim-
posable (Fig. 1A). When model-dependent analysis was car-
ried out, the E2 concentration-time data were best described
by a three-compartment open model. Coadministration of
progestogen was found to have no influence on the PK of E2,
either on the days within a treatment period or on the treat-
ment period itself.
The mean population values of the E2 primary PK pa-
rameters obtained with the model were as follows: CL/F, 207
liters/h; Vc/F, 178 liters; Q2/F, 130 liters/h; V2/F, 1100
liters; Q3/F, 161 liters/h; V3/F, 107 liters; duration of the
zero order input (TK0), 0.22 h; and endogenous baseline level
of E2, 12 pg/ml (Fig. 1C). The residual error terms were
estimated as 17% and 3.5 pg/ml for the multiplicative and
the additive parts, respectively. The secondary PK parame-
ters are reported in Table 1. The intra- and intersubject vari-
abilities of the main PK parameters for E2 were less than 28%,
with the exception of the interindividual variability of the
predicted total serum concentration (Cmax), which was 33%
(Table 2).
E1. With regard to E1, the mean endogenous serum level in
the postmenopausal women in this study 30 min before E2
administration was 12 7 pg/ml (mean sd), and this level
varied throughout the day (as assessed during the wash-out
period) from 11  6 to 14  9 pg/ml, for the lowest and
highest mean values, respectively.
A maximum mean E1 concentration of 317  153 pg/ml
(mean  sd) was observed 20 min after the nasal adminis-
tration of 300 g E2 as S21400 (Fig. 1B). Two and 4 h after
nasal administration, the E1 levels observed represented 33%
(i.e. 105 pg/ml) and 23% (i.e. 44 pg/ml), respectively, of the
maximum mean observed value after E2 treatment. Twenty-
four hours after E2 administration, the E1 levels were slightly
higher (33  20 pg/ml) than the endogenous pretreatment
levels. The E1 profiles observed on d 1, 14, and 28 were
superimposable. When model-dependent analysis was car-
ried out, the E1 concentration-time data were best described
by a three-compartment open model. None of the tested
covariates was found to influence the pharmacokinetics
of E1.
The mean population values of the E1 primary PK pa-
rameters obtained with the final model were as follows:
CL/F, 183 liters/h; Vc/F, 668 liters; Q2/F, 40 liter/h; V2/F,
2140 liters; Q3/F, 711 liter/h; V3/F, 866 liters; duration of the
zero order input (TK0), 0.30 h; and endogenous baseline level
of E1, 13 pg/ml (Fig. 1C). The residual error terms were
estimated to be 13% and 2.6 pg/ml for the multiplicative and
additive parts, respectively. The mean ratios of E1 to E2
systemic exposure and the secondary PK parameters of in-
FIG. 1. Mean E2 and E1 pharmacokinetics. A, Mean observed serum E2 concentrations vs. time. B, Mean observed serum E1 concentrations
vs. time. C, Observed endogenous E2 (F) and E1 (E) concentrations vs. time. The lines represent cubic spline through the observed and the
individual model predictions, respectively.
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terest are reported in Table 1. Intra- and intersubject vari-
abilities of the main PK parameters were higher for E1 than
for E2 (Table 2).
Pharmacodynamics: FSH serum levels
Mean FSH levels measured before E2 administration were
not statistically different (P  0.4) in the postmenopausal
women who had received E2 treatment compared with those
who had received E2 and progestogen treatment (118 7 and
117  7 mIU/ml, respectively). Statistical analysis revealed
no significant effect of either concomitant progestogen ad-
ministration or treatment sequence on FSH values during the
study. Consequently, these two factors were not taken into
account in subsequent analyses, and data from the first and
second treatment periods were pooled.
On d 1, the mean FSH serum level before E2 administration
(predose) was 117  5 mIU/ml and described a U time-
concentration curve over a 24-h period (Fig. 2). The lowest
FSH serum level was reached around 8 h after the admin-
istration of E2, with a value of 99  4 mIU/ml, i.e. 16  1%
decrease. There was a statistical difference between the FSH
levels measured at the different time points in the day (P 
0.0001): no change was observed between the mean values
pretreatment and those up to 20 min after the intranasal
administration of E2, but a continuous decrease was ob-
served between 20 min and 8 h after E2 administration. This
decrease was followed by an increase between 8–12 h (FSH
levels representing 86% and 91% of the pretreatment value,
respectively) and between 12 -24 h after the administration
of E2. Compared with mean pretreatment value, FSH levels
were different from 20 min to 12 h postadministration, but
were not different at 24 h. The FSH profiles observed on d 14
and 28 were very similar to the profile observed on d 1.
However, the mean pretreatment FSH serum level (for the
combined data of all treatments) was significantly (P 
0.0001) reduced on d 14 and 28 compared with that on d 1
(17% and 22%, respectively). Furthermore, the ampli-
tudes of the decrease in FSH levels were reduced compared
with that on d 1; maximum mean decreases were 18, 15,
and11 mIU/ml for d 1, 14, and 28, respectively. However,
when these decreases were expressed as a percentage of the
pretreatment FSH serum level, the amplitudes were quite
similar throughout the 28-d cycle: 15, 16, and 12%, for
d 1, 14, and 28, respectively.
A mechanistic-based PD model was used to describe the
FSH data (Fig. 3). A summary of the baseline FSH concen-
trations (FSH0), population and individual PD parameters
and their variabilities is provided in Table 3. The good agree-
ment between population and individual parameters sup-
ports the goodness of fits of the population PK/PD model
(Fig. 4, A–D). The additive residual error term of PD model
was estimated to be 4.8 mIU/ml (range, 4.2–5.3 mIU/ml).
The intrasubject variability in FSH levels calculated by
ANOVA on untransformed FSH values at baseline and 8 h,
when the maximal effect was observed, was low (10%), and
the intersubject variability in FSH levels was less than 42%.
Discussion
In the neuroendocrine regulation of the menstrual cycle,
E2 exerts a negative regulatory feedback effect on pituitary
FSH secretion and biosynthesis. This regulatory effect of E2
is exerted at two levels, directly at the pituitary level (17) and
indirectly at the hypothalamic level via modulation of GnRH
(18). It is well known that in normal women after the meno-
pause, gonadotropin levels rise initially, then decline with
age (19). Recently, Hall et al. (20) have shown that aging is
also associated with a marked decrease in free -subunit
pulse frequency. This decrease provides evidence that the
hypothalamic component of the reproductive axis can occur
independently of changes in gonadal hormone secretion (20).
TABLE 1. Model-dependent secondary pharmacokinetic parameters of E2 and E1
First 28-d treatment period
WO
Second 28-d treatment period
d 1 d 14 d 28 d 90 d 103 d 117
E2 parameters
Cmin (pg/ml) 21  6.8 19  4.9 20  4.3 20  4.8 23  7.5 21  5.7
Cmax (pg/ml) 1355  495 1476  544 1358  519 1318  533 1360  560 1270  477
AUCexo (pg/hml) 1511  528 1458  404
AUC24exo (pg/hml) 1328  398 1541  536 1361  487 1347  381 1524  452 1408  463
t1/2z (h) 11  5.6 8.0  2.7 9.4  2.9 9.6  2.6 13  13 9.4  2.7
E1 parameters
Cmax (pg/ml) 373  164 442  196 414  192 353  157 405  177 399  189
AUC24exo (pg/hml) 1135  724 1482  564 1449  574 1114  367 1552  564 1616  750
AUC24exo E1
AUC24exo E2
0.84  0.32 0.99  0.32 1.1  0.28 0.84  0.25 1.0  0.27 1.2  0.38
Values are the mean  SD.
AUC24exo, Area under the predicted concentration vs. time curve of exogenous compound calculated as AUC24exo dose/(predicted apparent
total clearance). For d 1 of each cycle, AUC24exo  AUC0-exo; Cmin, predicted minimum total serum concentration, just before an adminis-
tration; after single administration, predicted concentration just before the second administration (C24h); Cmax, predicted maximum total serum
concentration; t1/2z, terminal half-life; WO, 2-month wash-out.
TABLE 2. E2 and E1 intra- and intersubject variabilities
calculated over the six periods of serum collection
Variability (%)
E2 E1
Intrasubject Intersubject Intrasubject Intersubject
AUC24exo
a 23 27 41 36
Cminb 20 23 31 39
Cmax 27 33 32 38
a For d 1 and 90 AUC24exo is AUC0-exo.
b For d 1 and 90, 24 h.
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Therefore, to avoid this age-related decline in FSH levels, the
women included in the current study were at least 3 yr
postmenopausal, but were younger than 65 yr of age. It is
well established that oral and transdermal estrogen treat-
ments decrease FSH levels in women (11). However, this is
the first report of the PD response of FSH during estrogen
replacement therapy using nasal administration of E2 in
postmenopausal women. FSH pulse studies were not per-
formed, as pulsatile FSH release is difficult to assess due to
the slow metabolic clearance of the hormone (21, 22).
In relation to its PK, the effects of E2 on FSH after intranasal
administration appear to be rapid and transient. A decrease
FIG. 2. Mean observed serum E2 (F) and FSH (error bars corresponding to SEM) concentrations vs. time on d 1, 14, and 28 of both treatments,
with and without progestogen.
FIG. 3. FSH mechanism-based pharmacokinetic/pharmacodynamic model. Kout, First order rate constant for the loss of FSH; Kin, zero order
constant for production of FSH; Emax, maximum effect attributed to E2; IC50, concentration of E2 that produces half of the maximum inhibition;
Cp, plasma E2 concentration; Keq, rate constant of equilibration; AUC, area under E2 time to concentration curve during a dosing interval.
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in plasma FSH levels occurs within 20 min, reaching the
maximum decrease compared with baseline after 8 h, with a
return to basal FSH levels at 24 h. In addition, intranasal E2
administration does not seem to lower FSH values to those
of premenopausal women, which has been reported with
other estrogen treatments (19). Whereas the results of the
current study illustrate transient and short-term effects of
pulsed E2 exposure, more sustained effects on FSH have been
reported with other routes of administration where E2 ex-
posure is maintained throughout the day, such as with the
oral (23) and transdermal (9, 10, 11) routes. Studies per-
formed with administration of 2 mg micronized orally ad-
ministered E2 have shown a decrease in FSH serum levels,
as observed after intranasal administration. However, in con-
trast to the intranasal route, FSH levels were still significantly
suppressed 24 h after oral E2 administration (7). These dif-
ferences in FSH serum profiles between the intranasal, trans-
dermal, and oral routes are mostly explained by the differ-
ences in their plasma E2 profiles.
The present study provides further information than pre-
viously reported (12), especially about repeated administra-
tion, on the PK characteristics of E2 after intranasal admin-
istration. The results indicate that repeated treatments do not
modify the PK of E2, thus there is a rapid increase in E2 serum
concentrations within 15 min, which returns rapidly to about
10% of the peak value approximately 2 h after administra-
tion, and to untreated postmenopausal levels within 12 h.
The PK of E1 and E2 were shown not to depend on the
intranasal E2 timing of administration or on progestin co-
administration. No accumulation of E2 (ratio for accumula-
tion, 1.1) and a slight accumulation of E1 (ratio for accu-
mulation,1.4) were observed. Unlike oral administration of
E2, which results in a significant rise in the levels of the major
metabolite E1 due to the so-called first pass effect, (16, 24), an
E1/E2 systemic exposure ratio close to physiological values
(1:1) was shown in the present study. The PK profile after
intranasal E2 dosing led to an intra- and intersubject vari-
abilities that were relatively low for the area under the pre-
dicted concentration vs. time curve of exogenous compound
[AUC24exo; calculated as AUC24, exo dose/(predicted ap-
parent total clearance); for day 1 of each cycle, AUC24, exo
AUC0exo] of E2 (23% and 27%, respectively). Intra- and
intersubject variabilities were higher for the AUC24exo of E1,
reflecting variability due to the metabolite formation (41%
and 36%, respectively). For both estrogens, intra- and inter-
subject variabilities were of the same magnitude, showing
that the input phase was probably the main source of vari-
ability rather than the metabolism. In contrast, greater intra-
and intersubject variabilities in systemic exposures were
shown when E2 was administered either orally or transder-
mally (25, 26); poor absorbers have been reported with
patches (27). The exposure to exogenous E2 after intranasal
administration is, therefore, transient and reproducible.
Analysis of the serum FSH levels demonstrated that pre-
treatment serum FSH levels on d 14 and 28 were lower than
pretreatment FSH levels observed on d 1. This decrease in
pretreatment FSH levels over the 28-d cycle reflects the equi-
librium at the cellular level between the different comple-
mentary mechanisms regulating FSH synthesis, degradation,
and distribution of FSH isoforms. It is now established that
the proportion of the different isoforms of FSH in the blood
and pituitary tissue is affected by endocrine status (28). For
example, estrogen exposure in menopausal women shifts the
distribution of isoforms from acidic to more basic forms,
which have a shorter half-life in the circulation. Furthermore,
the relative proportion of the more basic FSH isoforms within
the pituitary tissue increases with the duration of the expo-
sure to E2. Consequently, the decrease in pretreatment FSH
levels observed after repeated E2 therapy might be explained
in part by an increase in more basic FSH isoforms.
Although our study does not enable us to distinguish
between a hypothalamic or a pituitary E2 effect, according to
the PK/PD model, we have shown that E2 modifies not only
FSH secretion, but also FSH synthesis. A direct pituitary
effect of estrogen on gonadotropin secretion has previously
been demonstrated by Clarke and Cummins (29) using a
model in long-term ovariectomized ewes in which the pitu-
itary had been disconnected surgically from the hypothala-
mus. In this model, long-term (6 months) estrogen treatment
had a negative feedback effect on the pituitary gland. Fur-
thermore, plasma FSH concentrations were reduced by ap-
proximately 50% after E2 treatment (30). Short-term regula-
tion of gonadotropin subunit mRNA levels by estrogen has
also been reported in both ovariectomized/hypothalamo-
pituitary-intact and ovariectomized/hypothalamo-pitu-
itary-disconnected ewes (31). In these animals, FSH mRNA
levels were found to be reduced 8 h after they had received
estradiol benzoate im. These experiments demonstrated that
estrogen feedback can cause rapid alterations in pituitary
gonadotropin subunit mRNA levels. Furthermore, in this
TABLE 3. FSH pharmacodynamic parameters and their variabilities
Parameter Variabilitya
Population estimate Individual (median) Intrasubject Intersubject
FSH0 initial (mIU/ml) 119 121 5.8 41
A constant (ml/pgh) 0.00015 0.00018 60 84
Keq (1/d) 0.099 0.088 86 105
Kout (1/h) 0.19 0.19 9.4 19
Emax 0.26 0.25 6.7 14
IC50 (pg/ml) 36 38 16 28
Hill factor 4.4 4.4
a Variabilities calculated by ANOVA on individual model parameters over periods 1 and 2. FSH0 initial, Baseline value of FSH before the
first E2 administration; A constant, multiplied by AUC gives the percent maximum decrease in FSH0 from FSH0 initial; Keq, rate constant
of equilibration; Kout, first order rate constant for the loss of FSH; Emax, maximum effect attributed to E2; IC50, concentration of E2 that pro-
duces half of the maximum inhibition.
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model, short-term changes in FSH mRNA were also re-
flected by changes in FSH secretion. In the current study the
effect of E2 on FSH secretion also appears to be reproduced
from one cycle to the next. During the second cycle of treat-
ment, FSH is even more sensitive to E2, although the plasma
levels of E2 are comparable in all the cycles. As this effect is
not related to either the route of administration or the bio-
availability of intranasal E2 it is therefore likely to result from
FIG. 4. FSH pharmacodynamic model: time course and goodness of fits. A, The full and dotted lines represent a cubic spline through the observed
data and the individual model prediction, respectively. B–D, Observed (Obs) FSH concentrations vs. individual predictions (IPred) in different
studies. Lines indicate identity. B, Results obtained in the present study after single and repeated intranasal administration at the dose of 300
g. C, Model validation using data from a study (12) with single dose intranasal administration of 100, 300, and 450 g. D, Model validation
using data from a study (13) with intranasal administration at doses of 100, 200, 300, and 400 g once a day.
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an increase in E2 sensitivity of the hypothalamus or the
pituitary.
A mechanism-based PD model linking the evolution of
FSH levels to E2 concentrations was developed, taking into
account the complex action of E2 on FSH. This model ade-
quately characterized both the short-term (over 24 h) and
mid-term (over 28 d) PD response after intranasal adminis-
tration of E2 once daily for 28 d. Two PK/PD submodels were
necessary to describe the dual actions of E2 on FSH. The first
model (describing the inhibition of secretion that takes place
within several hours) was an indirect inhibitory sigmoid
Emax model relating the plasma concentrations of E2 to the
serum FSH levels. The second model (describing the inhi-
bition of the biosynthesis that takes place within several
days) was a drug exposure response time model relating the
E2 exposure to the predose values of FSH. The pulsed PK E2
profile observed after intranasal treatment is associated with
a transient daily decrease in FSH, with a relatively low in-
trasubject variability compared with the intersubject vari-
ability. To challenge our integrated PK and physiological
indirect PD model and validate the short- and mid-term
effects of E2 on FSH concentrations, a Bayesian feedback
estimation was performed on a single-dose S21400 study (12)
and an S21400 dose-ranging study (13). The good agreement
between the observed concentrations, the population, and
the individual predictions through the different situations
(doses, duration) supports the concept of short- and mid-
term inhibitory actions of E2 on FSH levels.
Interestingly, dydrogesterone was not found to modify
FSH levels. This finding is in accordance with previous re-
sults in premenopausal women (32) showing that dydroges-
terone does not modify the basal level of FSH. Our data favor
a low antigonadotropic activity compared with other pro-
gestrogens. Progesterone has been shown to induce a 56%
decrease in FSH basal levels (P  0.0001 compared with
baseline) when administered with transdermal E2 treatment
in postmenopausal women (11). The low antigonadotropic
activity of dydrogesterone is confirmed by publications
showing that it is unable to block ovulation (33–36).
In summary, PK analyses performed during this study in
postmenopausal female volunteers showed that after intra-
nasal administration the kinetic profile of serum E2 shows a
transient exposure leading to pulsed estrogen therapy. This
profile is associated with an E1/E2 ratio comparable to that
seen physiologically and has low intra- and interindividual
PK variabilities. The results of the current study also docu-
ment the PD effects of repeated pulsed 17-E2 treatment on
the serum FSH profile; daily transient exposure to E2 elicits
a transient decrease in FSH levels, which is thought to be
related to direct FSH secretion regulation. Repeated treat-
ment also produces mid-term effects, as shown by a pro-
gressive decrease in FSH basal levels during the treatment
period, an effect that may be related to pituitary FSH syn-
thesis. It thus appears that E2, when administered via pulsed
estrogen therapy, may act on serum FSH levels through two
distinct pathways.
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